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Abstract
Understanding the critical points in the blood transfusion chain through reporting, monitoring  
and analysis of donor and transfusion adverse reactions, transfusion errors, near miss events 
and their (potential) consequences is essential for defining of appropriate prevention and  
co rrective measures and is therefore crucial for improvement of donor and patient safety.
The system of reporting transfusion-related adverse reactions was implemented in Portugal in 
2008 however the process of notification of donor adverse reactions, blood establishment and 
hospital blood bank errors and near miss events was in use since 2009. As regards frequency 
and severity, the data concerning donor adverse reactions are consistent with data reported in 
medical literature and underline the safety of blood donation in Portugal.
The most critical area for hospital blood bank near miss events and errors is the clinical area. 
In most of the cases these events are associated with patient misidentification. Correct patient 
identification must be considered the core clinical skill as errors due to misidentification have 
major impact in every field of medicine, particularly in transfusion where such errors may even 
be fatal. However, with effective education, training and competency assessment most of such 
errors and events are preventable and can be eliminated.
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Introduction
Blood supply depends entirely on the daily 
commitment of donors who are exposed to poten­
tial risk of discomfort and complications related to 
the procedure of blood collection.
Blood and apheresis donations are generally 
considered to be safe with a low incidence rate of 
adverse reactions. However, in order to further 
enhance blood donation safety it is essential to 
monitor and analyze adverse reactions.
Although many international standards recom­
mend that donors should be informed of donation 
risks, pre donation informing is primarily focused 
on risk activities relevant to the safety of the 
recipient. 
In order to improve the safety of the patient, it 
is essential to understand the critical areas in the 
blood transfusion chain. This aim can be achieved 
through focusing attention on reporting, monitor­
ing and analysis of transfusion adverse reactions, 
as well as transfusion errors, near miss events and 
their potential consequences.
In Portugal the Instituto Portugues do Sangue 
e da Transplantação (Portuguese Blood and Trans­
plantation Institute) is the institution responsible 
at national level for regulation of activities related 
to transfusion medicine, transplantation and en­
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surance of the safety of blood collection, testing, 
processing, storage and distribution of human blood, 
blood components, organs, tissues and cells of hu­
man origin. The scope of the responsibilities of this 
institution includes also the promotion of commu­
nication with hospital blood banks and functioning 
of the Portuguese Hemovigilance System (PHS).
The PHS was implemented in 2008 follow­
ing the transposition into the national law of the 
relevant European directives: the European Union 
Blood Safety Directive (2002/98/EC) which applies 
to all European countries since February 2005 and 
ensures health protection by setting standards 
of quality and safety for the collection, testing, 
processing, storage and distribution of blood as 
well as Directive 2005/61/EC which implements 
Directive 2002/98/EC as regards traceability and 
notification of serious adverse reactions and events 
requirements [1, 2]. PHS is managed by a steering 
committee which includes representatives of the 
Portuguese Blood and Transplantation Institute 
in cooperation with the competent authority as 
regards the reactions and adverse events related 
to the quality and safety products, blood and blood 
components. 
The notification system currently covers the 
entire transfusion chain, from donor to recipient 
as well as collection of data on the activities of 
blood establishments, hospital blood banks and 
facilities. The database is accessible through 
a web site and supplies surveillance and monitoring 
information which are used for data analysis and 
risk calculation, benchmarking as well as education 
and training.
The notification system includes not only seri­
ous adverse reactions and events but also donor 
adverse reactions, all the recipient adverse reac­
tions as well as all the events (errors and near miss 
events) which occur in the blood transfusion chain. 
Available are also notifications of exclusion when 
institutions have no events or reactions to report 
as well as reports on the activity of blood estab­
lishments and hospital blood banks. The system 
of reporting transfusion­related adverse reactions 
was implemented in Portugal in 2008 however the 
process of notification of donor adverse reactions, 
blood establishment and hospital blood bank er­
rors and near miss events was in use since 2009. 
Reporting on the activities of blood establishments 
and hospital blood banks on web site was imple­
mented in 2012. All serious adverse reactions 
and serious adverse events, errors and near miss 
events are reported to the European Commission.
At the end of 2012 [3] there were 294 notifiers 
as part of the Portuguese Haemovigilance System 
that belonged to 188 public and private institutions: 
1 blood establishment, 33 institutions which simul­
taneously combine the functions of blood establish­
ments and hospital blood bank, 74 hospital blood 
banks and 80 facilities. Up to date the information on 
errors and near misses in blood establishments are 
scarce and the implementation of a sentinel event 
notification process is necessary. Therefore the aim 
of this report was to analyze the frequency and se­
verity of donor adverse reactions and hospital blood 
bank errors and near miss events in order to define 
appropriate prevention and corrective measures to 
improve the safety of blood donations and patients.
Material and methods
A retrospective analysis of donor adverse 
reactions and hospital blood bank errors and near 
miss events reported to the PHS in 2012 has been 
performed.
Data concerning donor adverse reactions was 
recorded following local procedures and classified 
using the ISBT/IHN standard for surveillance of 
donation complications [4]. Only the reactions 
that required any kind of clinical intervention were 
reported, as defined by the Portuguese haemovigi­
lance steering committee. The data referring to 
hospital blood bank errors and near miss events 
were classified according to error type and stage 
of occurrence in the transfusion chain with special 
focus on the clinical stage i.e. from request for 
blood component to its transfusion.
To make the analysis of the results easier the 
clinical stage of the transfusion chain was divided 
into three parts: the clinical area before the order 
for blood component is issued to the blood bank; 
the area of hospital blood bank; the clinical area 
after the blood component is delivered. 
According to the European Union blood safety 
Directives blood establishment [1] is defined as any 
structure or body that is responsible for any aspect 
of the collection and testing of human blood or 
blood components, whatever their intended pur­
pose, and their processing, storage, and distribu­
tion when intended for transfusion. The definition 
does not include hospital blood banks.
Hospital blood bank [1] shall mean a hospital 
unit which stores and distributes and may perform 
compatibility tests on blood and blood components 
exclusively for use within hospital facilities, includ­
ing hospital based transfusion activities.
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Facilities [1, 6]. means hospitals, clinics, manu­
facturers, and biomedical research institutions to 
which blood or blood components may be delivered.
According to ISBT/IHN [4] a donor adverse 
reaction is an undesirable response or effect in 
a donor temporally associated with the collection 
of blood or blood component. 
Severity [4] of donor adverse reactions is 
graded in two main levels, severe and non­severe, 
based on requirements for treatment and on out­
come, in a way which corresponds to other systems 
in use internationally (i.e. ISBT for grading of 
adverse reactions to blood transfusion, European 
Commission for grading of transfusion reactions, 
FDA for grading of drug adverse events). 
Conditions which define a donor adverse re­
action as severe are [4]: hospitalization if it was 
attributable to the complication; intervention to 
preclude permanent damage or impairment of 
a body function; to prevent death (life­threatening); 
symptoms causing significant disability or incapac­
ity following a complication of blood donation and 
persisting for more than a year after the donation 
(long term morbidity); death if it follows a complica­
tion of blood donation and is possibly, probably or 
definitely related to the donation. The non-severe 
complications are complications which do not satisfy 
any of the requirements for being severe.
The grading of imputability [4] of donor ad­
verse reactions was defined as the strength of 
relationship between donation and the complication 
and can be:
 — Definite (certain): when there is conclusive 
evidence beyond reasonable doubt for the 
relation.
 — Probable (likely): when the evidence is cle­
arly in favor of a relation 
 — Possible: when the evidence is indetermina­
te for attributing the adverse reaction to the 
donation or alternate cause. 
 — Unlikely or doubtful: when the evidence is 
clearly in favor of attributing the complication 
to other causes.
 — Excluded: when there is conclusive evidence 
beyond reasonable doubt that the complication 
is not related to donation. 
An adverse event [5] is an undesirable and 
unintended occurrence before, during or after 
transfusion of blood or blood component which 
may be related to the administration of the blood 
or component. It may be the result of an error or 
an incident and it may or not result in a reaction 
in a recipient. Adverse events shall mean all the 
errors and near miss events.
An error is defined as a deviation from the 
standard procedures or policies which had not been 
detected before the transfusion was administered 
and which may result in the transfusion of an inap­
propriate blood component or adverse reaction. 
A near miss event [5, 6] is defined as an error 
or deviation from standard procedures or policies 
that is discovered before the start of the transfusion 
and that could have led to a wrongful transfusion 
or to a reaction in a recipient. 
Results and discussion
Donor adverse reactions
A total of 1455 donor adverse reactions (DAR) 
were reported to the Portuguese Haemovigilance 
System during 2012, with a rate of 3.7/1000 do­
nations and 5.88/1000 donors (similar data were 
reported for the years 2010, 2011). 
These adverse reactions occurred at differ­
ent stages of the donation process: 36.3% were 
reported during blood donation (from needle inser­
tion to needle removal); 58.75% after the donation 
(37.25% after needle removal and 21,5% after the 
donor stands up from blood donation bed and before 
he leaves the blood donation site) and approxi­
mately 5% (4.95%) were donor delayed adverse 
reactions after the donor left the blood donation 
site (Figure 1).
During blood donation
After needle removal
Ambulatory donor on site
Donor has left blood donation site
37.25%
36.3%
5%
21.5%
Figure 1. Donor adverse reactions at different stages 
that refer to blood donation
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Of the reported DAR 95.95% were non severe 
while 4.05% were severe and required medical 
care (hospital admission or urgent medical inter­
vention). Injuries, falls with injury or wounds, oc­
curred in 1,09% of the reactions. Severe reactions 
represent 15/100 000 donations.
As concerns imputability levels: 76.36% of 
the reactions were probable, likely related to the 
event, 18.63% were definite, certain and 4.88% 
were possible. Further analysis of the data revealed 
that the most common complication were imme­
dia te vasovagal reactions which were observed in 
77.4% of all reactions and that corresponds to 0.3% 
of the overall number of donations. Of the overall 
number of reactions 12.9% were reactions with 
local symptoms: haematoma, arterial puncture, 
delayed bleeding, nerve irritation/injury, tendon 
injury and pain at venipuncture site. Haematoma 
reactions were 11.5% of the overall number of 
reactions (0.04% of the overall number of dona­
tions) (Figure 2).
In 2012 in Portugal a total of 4769 apheresis 
procedures were performed and 56 reactions were 
reported (3.8% of the overall number of reactions 
were related to apheresis donation). These reac­
tions were complications such as haematoma (the 
most frequent) and citrate reactions. 
In 2012 in Portugal 51.6% of the donors were 
males, and DAR were more frequently reported 
for males than for females (52.78% of the overall 
reactions). Of the adverse reactions approximately 
39.9% occurred in first-time donors and 32.2% in 
donors with 1 to 4 previous donations. The remain­
ing 30% is attributed to donors who had donated 
blood 5 to 31 times.
As regards age distribution of donors who 
experienced adverse reactions such complications 
were observed more frequently in young donors 
(18–24 years who represented 13.4% of the whole 
donor population. In this age group 24.57% of all 
the adverse reactions were reported (Figure 3).
Reports on errors and near miss events
A total of 166 near miss events and 28 errors 
were reported to the Portuguese Haemovigilance 
System with a rate of 4.9 near miss and 0.82 
errors/10 000 red blood cell (RBC) units transfused. 
We observed a maximum of three different types of 
near miss events or errors per report (transfusion 
event) and a minimum of one.
The reported near miss events occurred 
mostly in clinical areas (81.92%) before issue of 
the order to the blood bank (2.41% in the clinical 
decision process, 10.84% in filling the request form 
and 68.67% during sample collection). In hospital 
blood banks there occurred 13.25% of near miss 
events while 1.2% in the clinical areas during the 
transfusion process (Figure 4).
Figure 2. Donor adverse reactions following whole 
blood and apheresis donations (% of all donations)
Figure 3. Age distribution in donors who suffered ad-
verse reactions against donor age in Portugal
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The reported errors were distributed as fol­
lows: in 17.85% of the cases the errors occurred 
in the clinical area before the order to the blood 
bank, in 21.43% in hospital blood banks and in 
53.57%. in the clinical areas during transfusion 
process (Figure 5).
The most prevalent errors occurring in clini­
cal areas were the transfusions of the wrong unit 
to the wrong patient, administration of the wrong 
ABO group with or without ABO compatibility and 
incorrect sample collection. 
The most prevalent near miss events were 
associated with wrong name on the tube, sample 
collection from the wrong patient and labeled with 
the intended patient’s identification data or sample 
collection from the intended patient but labeled 
with other patient’s identification data. 
Most of these near miss events were asso­
ciated with patient misidentification. Analysis of 
2012 data indicates that for every wrong blood in 
tube error (4 cases) there were about 30 near miss 
sample mistakes (120 cases) (Figure 6).
Errors and near miss events which occurred in 
blood banks were associated with improper labeling 
and transcription errors as well as with the issue 
of inappropriate blood component. As regards loca­
tion for errors and near miss events, we observed 
that 92.7% of near miss events were detected in 
hospital blood banks while 57.14% of the errors in 
the clinical areas. 
In 18 cases of reported errors (64%) conse­ 
quences to the patient were found. When we 
compare this data with the data for the year 2011 
we observe a decrease in the number of reported 
errors but their severity level is higher. In 2011 
only 12% of the reported errors were found to have 
consequences to the patient.
In 2012, a total of 12 ABO incompatible ad­
verse transfusion reactions were reported to the 
Portuguese Haemovigilance System. Seven (7) 
of these reactions (58%) were severe, 2 were life 
threatening (16.6%) and 2 were fatal (16.6%). In 
what concerns imputability levels, 50% of these 
reactions were certain 16.6% probable and 25% 
possible. 
In 2012 other adverse transfusion reactions 
were also reported: 46.8% were febrile non hemo­
lytic reactions, 22.6% allergic reactions, 7.8% 
delayed serologic reactions, 5.8% transfusion 
associated dyspnea, 4.6% transfusion associated 
circulatory overload, 2.4% hipotensive transfusion 
reactions, 0.36% anaphylactic reaction, 0.18% (one) 
TRALI and 7.3% were classified as other reactions.
In 2012 ABO Incompatible Adverse Transfu­
sion Reactions represented 2.2% of the overall 
number of reports of adverse transfusion reactions, 
Figure 4. Areas of the blood transfusion chain where the 
reported near miss events occurred
Figure 5. Areas of the blood transfusion chain where the 
reported errors occured
Clinical area before order to the HBB — clinical decision
Clinical area before order to HBB — request
Clinical area before order to HBB — sampling
Hospital blood bank (HBB)
Clinical area following issue — transfusion
68.67%
10.84%
13.25%
1.20%2.41%
Clinical area before order to the HBB — request and sampling
Hospital blood bank (HBB)
Clinical area following issue — transfusion
53.57%
17.85%
21.43%
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*Innapropriate T decision means that there was no need for transfusion order. The evaluation is performed by the 
hospital/institution reporting body and validated by the Portuguese Haemovigilance Steering Committee
Table 1. Number and severity of hemolytic reactions 
due to ABO incompatibility in the period 2008–2012
Non  
severe 
Severe Life  
threatening
Death Total
2008 5 5 0 0 10
2009 4 8 0 0 12
2010 1 6 2 0 9
2011 1 2 2 2 7
2012 1 7 2 2 12
Total 12 28 6 4 50
with a rate of 3.1/100 000 red blood cells units 
transfused.
As compared to the previous years the fre­
quency of ABO incompatible reactions decreased 
(3.6/100 000 RBC in 2008 and 2009; 3.8/100 000 
RBC in 2010; 2.4/100 000 RBC in 2011) while the 
level of severity increased (Table 1).
Conclusions
The data referring to the frequency and sever­
ity of donor adverse reactions is consistent with 
literature reports and points to the safety of blood 
donation. The rate for severe adverse reactions was 
low; only 4.05% of the reactions were severe and 
required the donor to seek medical care and that 
corresponds to 15/100 000 donations.
Most critical for both near miss events and 
errors is the clinical area rather than the hospital 
blood bank laboratory. Near miss events occur 
more frequently during the request and sampling 
process while the errors mostly occur during the 
procedure of transfusing blood components.
Employees of hospital blood banks are more 
prone to detect non­conformities than those who 
work in clinical areas. Of the near miss events 
92.7% were detected in hospital blood banks where 
screening of all the requests/orders is performed 
and the comparison with patient’s transfusion 
32 www.jtm.viamedica.pl
Journal of Transfusion Medicine 2014, tom 7, nr 1
history takes place. Specialists in transfusion 
medicine can largely contribute to the analysis of 
causes for error and near miss events.
Correct patient identification must be consid­
ered the crucial clinical skill because identification 
errors have significant impact in every area of 
medicine, particularly in transfusion. Awareness 
of the importance of correct identification and its 
impact on the safety of the patient who is scheduled 
for transfusion is fundamental as any such error 
may be fatal. 
The majority of events which threaten donor 
and patient safety are preventable and can be 
avoided with careful and systematic education, 
training and competency assessment of all staff 
involved in the transfusion chain. 
As for other preventive measures which 
could be used to eliminate or reduce the number 
of donor adverse reactions and that go beyond the 
requirements for staff education and training we 
can mention careful donor vigilance and strategies 
to reduce vasovagal reactions. Donors could be 
supplied with better educational materials to instruct 
them how to avoid such reactions and report any 
medical problems that may occur within days or 
weeks of donation. 
What seems equally important is to support 
the patient identification procedure with new 
identification techniques, to organize more regular 
audits and promote a closer liaison and coopera­
tion between a well­trained, enthusiastic, active 
Hospital Transfusion Committee and the staffs of 
the hospital blood bank and clinical areas. 
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